Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

AstraZeneca CEO Leaving As Profits Slide, Warns On Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 08:56am CEST

AstraZeneca PLC (AZN) Thursday said Chief Executive David Brennan is leaving after the troubled drug maker missed its first-quarter earnings and sales forecasts and cut its full-year profit targets yet again.

AstraZeneca, which reports in dollars, said net profit in the first three months of 2012 fell 44% to $1.64 billion from $2.91 billion a year earlier, missing analysts' expectations of $2.0 billion. Revenue was down 11% at $7.35 billion, compared with $8.29 billion a year earlier, worse than the $7.98 billion expected in a survey of 10 analysts.

Brennan, who used the update to announce his retirement, said, "The anticipated impact from the loss of exclusivity on several brands, together with challenging market conditions, has made for a difficult start to the year in revenue terms.

"Delivery on our restructuring plans and continued discipline on operating costs, together with the benefits from a lower tax rate, will only partially mitigate the revenue pressures. As a result we have lowered our core EPS [earnings per share] target for the full year to the range of $5.85 to $6.15."

The company previously foresaw core EPS coming in this year at $6.00 to $6.30, after $7.28 in 2011.

Brennan, an American, has been CEO since the start of 2006. Chief Financial Officer Simon Lowth will act as interim chief executive from June until a permanent successor is in place.

AstraZeneca faces crucial patent expiries between now and 2015 on products such as antipsychotic Seroquel and ulcer medicine Nexium, and the loss of patent protection in the U.S. in 2016 for its best-selling drug, heart drug Crestor. Coupled with a thinner late-stage pipeline and a mixed longer-term research and development track record, the U.K.'s No. 2 drug maker by sales has taken an aggressive approach to costs, shrinking operations and cutting thousands of jobs, while keeping cash flowing to shareholders.

In February, AstraZeneca announced it was cutting around 7,300 jobs as part of the company's ongoing cost-savings program. The first phase, launched in 2007, was aimed at improving long-term competitiveness and productivity. The second phase, announced in January 2010, envisioned the loss of up to 10,400 jobs by 2014.

Describing its outlook for 2012, the company said in a statement that "we now expect the decline in revenue for the full year will be in the range of the low to mid-teens in constant-currency terms."

AstraZeneca, which spent $5.6 billion last year buying back its own shares, Thursday said it spent $912 million in the first quarter on net stock repurchases.

AstraZeneca shares ended Wednesday at 2841 pence, down 6% on year-earlier levels.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -0.31% 637.3 Delayed Quote.12.45%
ASTRAZENECA -0.91% 5331 Delayed Quote.5.04%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
01:32pInitiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug..
12:44pASTRAZENECA : With an AstraZeneca cancer drug in one hand, $37M in the other, Sh..
06/20ASTRAZENECA : Scotland to house world-first manufacturing innovation centre
06/19FASTER MEDICINE : 56 million innovation centre for Scotland
06/19ASTRAZENECA : to Share Latest Data from an Industry-Leading Portfolio That Aims ..
06/19ASTRAZENECA : Medicines manufacturing centre planned to strengthen UK pharma
06/19ASTRAZENECA : to share latest data from an industry-leading portfolio that aims ..
06/18FASTER MEDICINE : £56 million innovation centre for Scotland
06/16ASTRAZENECA : £56m medicine base is set for Inchinnan
06/152.5B U.K. fund, Alzheimer`s failure, Alexion-Complement, Targovax tumbles and..
More news
News from SeekingAlpha
06/19ALZHEIMER'S DISEASE : A History Of Drug Failures 
06/19Allena Pharma to file IND for ALLN-346 in H1 2019 
06/15Avoiding The 'Black Hole' Of Disease Development 
06/153 THINGS IN BIOTECH, JUNE 14 : Another Big Win In A Rare Area For Merck 
06/14YOUR DAILY PHARMA SCOOP : Sage On Accelerated Path, GenSight Positive Data, Astr.. 
Financials ($)
Sales 2018 22 361 M
EBIT 2018 5 330 M
Net income 2018 1 982 M
Debt 2018 14 629 M
Yield 2018 3,88%
P/E ratio 2018 37,38
P/E ratio 2019 30,22
EV / Sales 2018 4,66x
EV / Sales 2019 4,39x
Capitalization 89 519 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 74,5 $
Spread / Average Target 5,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA5.04%89 519
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625